0114 232 9292 connect@medilink.co.uk

QuantuMDx receives grant funding from Gates Foundation for diagnostic to reach the missing 4.3 million TB cases a year

Newcastle upon Tyne, QuantuMDx has announced that it has received funding from the Bill & Melinda Gates Foundation to further develop and test its CAPTURE-XT™ pathogen concentration technology and Q-POC™ molecular diagnostic (MDx) platform for rapid low cost TB detection and drug susceptibility testing (DST) in response to World Health last-storyOrganisation target product profiles. The technology is being developed for introduction into peripheral microscopy centres, clinics and hospitals in high burden countries, finally providing a low cost MDx solution to reach the 4.3 million people with TB who are ‘missed’ by healthcare systems each year.

The project will bring together experts from QuantuMDx, the Gates Foundation’s TB Program, FIND, Yale University and St George’s University of London, to further develop and test the CAPTURE-XT™ and Q-POC™ technologies on a blinded cohort of FIND’s well-characterized sputum samples. The ultimate aim is to seamlessly integrate Q-POC™ technologies into existing microscopy centres for the rapid detection of TB and DST.

Elaine Warburton OBE, QuantuMDx’s CEO, said: “We are thrilled that the Gates Foundation is funding this project. A 2015 KPMG report estimated that, without urgent action, some 75 million additional people could die of TB over the next 35 years, at a global economic cost of $16.7 trillion. This is simply unacceptable, and the costs are unsustainable. I believe our Q-POC™ technologies will truly provide that elusive solution to early TB detection leading to quick and precise treatment thus reducing disease transmission and death.”

Comments are closed.